CSL LTD
CSL is a biopharmaceutical company based in Melbourne, Australia. Through CSL Behring, it provides plasma-derived medicines, gene therapies and recombinant products, including treatments for immunology, blood, cardiovascular and metabolic, respiratory, and transplant conditions. CSL Seqirus supplies influenza products and pandemic services to governments. CSL Vifor focuses on treatments for iron deficiency and kidney disorders. The company also licenses its intellectual property.
No enriched coverage for $CSLLY in the last 7 days.
No SEC Form 4 filings for $CSLLY in the last 30 days.
See all $CSLLY insider activity →CSL Limited (ASX:CSL; USOTC:CSLLY) appointed Deborah Waterhouse as CEO, effective February 1, 2027. She currently leads ViiV Healthcare, a GSK joint venture with £7.7B sales. Waterhouse has 25+ years in pharma, including roles at GSK. She will earn £1.5M base salary, with incentives and stock units. Gordon Naylor remains interim CEO until her start.
RBC Capital analysts maintained Buy ratings on CSL (CMXHF), Ionis Pharmaceuticals (IONS), and Cormedix (CRMD). CSL's price target is A$215.00, IONS's is $85.00, and CRMD's is $14.00. Analysts' consensus ratings are Moderate Buy for CSL and Strong Buy for IONS and CRMD.
CSL and Alentis Therapeutics have partnered to develop and commercialize lixudebart, a potential first-in-class therapy for rare kidney and liver diseases. CSL will pay Alentis $355 million upfront and up to $1.2 billion in milestones. Lixudebart is in Phase 2 trials for AAV-RPGN and will be tested for FSGS and PSC. CSL will fund further trials and share global profits. According to the companies, lixudebart has shown promising results in early trials.
Recent CSLLY coverage spans financial news, regulation and corporate actions.
Leadership change may influence CSL's strategic direction and investor sentiment.
RBC Capital analysts maintained Buy ratings on CSL (CMXHF), Ionis Pharmaceuticals (IONS), and Cormedix (CRMD). CSL's price target is A$215.00, IONS's is $85.00, and CRMD's is $14.00. Analysts' consensus ratings are Moderate Buy for CSL and Strong Buy for IONS and CRMD.
The partnership adds a significant upfront cash inflow and future milestone upside, likely boosting CSL's near‑term valuation.
Tariff reprieve may improve cost structure despite price cuts.
The agreements provide pricing certainty and signal a large capital outlay, likely supporting the stock in the medium term.
AlphAI scores every news story that mentions CSLLY with an AI model for sentiment and relevance, and aggregates insider trades from CSL LTD's SEC EDGAR Form 4 filings. Figures refresh continuously.
CSL Limited (ASX:CSL; USOTC:CSLLY) appointed Deborah Waterhouse as CEO, effective February 1, 2027. She currently leads ViiV Healthcare, a GSK joint venture with £7.7B sales. Waterhouse has 25+ years in pharma, including roles at GSK. She will earn £1.5M base salary, with incentives and stock units. Gordon Naylor remains interim CEO until her start.
RBC Capital analysts maintained Buy ratings on CSL (CMXHF), Ionis Pharmaceuticals (IONS), and Cormedix (CRMD). CSL's price target is A$215.00, IONS's is $85.00, and CRMD's is $14.00. Analysts' consensus ratings are Moderate Buy for CSL and Strong Buy for IONS and CRMD.
CSL and Alentis Therapeutics have partnered to develop and commercialize lixudebart, a potential first-in-class therapy for rare kidney and liver diseases. CSL will pay Alentis $355 million upfront and up to $1.2 billion in milestones. Lixudebart is in Phase 2 trials for AAV-RPGN and will be tested for FSGS and PSC. CSL will fund further trials and share global profits. According to the companies, lixudebart has shown promising results in early trials.
President Trump's administration signed drug-pricing agreements with nine mid-sized pharmaceutical companies, including Astellas Pharma, Teva, and UCB, to lower U.S. drug prices under the MFN proposal. Companies agreed to reduce prices and invest $19.6B in U.S. manufacturing, with some contributing APIs to a government reserve. The deals cover 89% of the branded drug market, expanding beyond initial Big Pharma focus.
CSL (ASX:CSL; USOTC:CSLLY) has agreed with the U.S. government to lower drug prices and invest $1.5 billion in U.S. manufacturing. The deals include pricing adjustments for Medicaid and new therapies, and a manufacturing expansion in Illinois. The company expects no material impact in fiscal 2027.
